Consumer Defensive
Live Price
Offline$0.086
+0.00% today
1Y Change
-48.10%
Window
Jun 20, 2025 → Jun 16, 2026
Coverage: 254 bars · Jun 20, 2025 → Jun 16, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
EC Healthcare (UNHLF) is a Consumer Defensive stock with a market cap of $550.00M and listed on OTC. The stock last traded around $0.09 and down 48.1% across the available one-year price window (Jun 20, 2025 → Jun 16, 2026). Baseline metrics include revenue growth of -1.7%, EPS growth of -775.0%, a dividend yield of 0.0%. What stands out right now is revenue -1.7%, EPS -775.0%, free cash flow +30.0% with operating margin -6.0% and ROIC -5.7%. Valuation is more restrained than many high-expectation growth names at price/sales 0.1. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines UNHLF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Consumer Defensive peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
UNHLF
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
UNHLF Max Drawdown
-63.85%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for UNHLF and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$2.1B
-28.7% YoY
FY Net Income
$192.9M
-2.3% YoY
Free Cash Flow
$471.7M
+35.5% YoY
Revenue Growth
-1.7%
EPS Growth
-775.0%
Gross Margin
74.8%
Net Margin
-4.8%
Income statement
HKD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 4.1B | 4.2B | 3.9B | 2.9B | 2.1B |
| Gross Profit | 3.3B | 3.5B | 3.3B | 2.6B | 1.8B |
| Operating Income | 95M | 109M | 219M | 363M | 279M |
| EBITDA | 619M | 743M | 787M | 803M | 599M |
| Net Income | -167M | -19M | 70M | 198M | 193M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
HKD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 1.0B | 554M | 710M | 870M | 936M |
| Total Assets | 5.0B | 5.4B | 5.5B | 4.9B | 3.8B |
| Total Liabilities | 2.8B | 3.0B | 3.1B | 2.5B | 2.2B |
| Shareholder Equity | 1.8B | 2.0B | 1.9B | 1.9B | 1.3B |
| Total Debt | 1.3B | 1.6B | 1.5B | 941M | 1.0B |
| Net Debt | 339M | 1.1B | 822M | 71M | 94M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
621M
+2.0% YoY
Capital Expenditures
149M
+42.7% YoY
Free Cash Flow
472M
+35.5% YoY
Key ratios
Gross Margin
74.8%
Operating Margin
-6.0%
Net Margin
-4.8%
ROE
-10.7%
Debt / Equity
0.93x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.